Md. Jashim Uddin has completed his Ph.D. at the age of 32 years from Shinshu University and postdoctoral studies from University of Alberta. He is a ‘Research Assistant Professor’ of Biochemistry at the Vanderbilt University School of Medicine. He has developed new drug design concepts for cyclooxygenase-2 (COX-2) inhibition. Also, he has contributed significantly in the development of cyclooxygenase-2 (COX-2) targeted imaging agents for early detection of cancer. He has developed Fluorocoxib A that has been marketed for pre-clinical applications. He has published more than 30 scientific publications in the world’s leading organic, bioorganic, medicinal chemistry, and cancer research journals. Md. Jashim Uddin has completed his Ph.D. at the age of 32 years from Shinshu University and postdoctoral studies from University of Alberta. He is a ‘Research Assistant Professor’ of Biochemistry at the Vanderbilt University School of Medicine. He has developed new drug design concepts for cyclooxygenase-2 (COX-2) inhibition. Also, he has contributed significantly in the development of cyclooxygenase-2 (COX-2) targeted imaging agents for early detection of cancer. He has developed Fluorocoxib A that has been marketed for pre-clinical applications. He has published more than 30 scientific publications in the world’s leading organic, bioorganic, medicinal chemistry, and cancer research journals.

Gastroenterology